ClinicalTrials.gg
CompletedNCT02373202Updated Jan 30, 2018Results posted

A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

A Phase 3 interventional study of Sarilumab and Sulfasalazine in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 40 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-01-30.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
11th of 22
91 · median 88
Started
2015
with 2 others
Phase 3
9 of 22
1 open now
Registered
15th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 11th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 15th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

To document the long-term safety of sarilumab added to non-methotrexate (non-MTX) disease-modifying antirheumatic drugs (DMARDs) or as monotherapy.

Secondary Objective:

To document the long term efficacy of sarilumab added to non-MTX DMARDs or as monotherapy.

Read the detailed description

Total study duration was up to 62 weeks: Up to 4-week screening period, 52-week treatment period, and 6-week post-treatment follow-up period.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of rheumatoid arthritis (RA), according to the American College of Rheumatology/The European League Against Rheumatism (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria with >=3 months disease duration.

Moderately to severely active RA defined as:

  • At least 4 of 68 tender joints and 4 of 66 swollen joints at screening visit.
  • High sensitivity C-Reactive Protein (hs-CRP) >=4 mg/L or Erythrocyte Sedimentation Rate (ESR) >=28 mm/hr at screening visit.

For the combination stratum:

Participants who had continuous treatment with non-biologic DMARDs other than MTX for at least 12 weeks prior to the randomization and on a stable dose for a minimum of 6 weeks prior to screening.

For the monotherapy stratum:

Participants who per investigator judgment were any of inappropriate, intolerant or inadequate to MTX treatment.

Exclusion criteria

Exclusion criteria:

Participants \<20 years of age. Prior treatment with tumor necrosis factor (TNF) antagonists or any other RA-directed biologic agents without the appropriate off-drug period prior to screening.

Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Sarilumab 150 mg q2w + DMARDs

    Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.

    Drug: Sarilumab · Drug: Sulfasalazine · Drug: Leflunomide · Drug: Bucillamine · Drug: Tacrolimus · Drug: Mizoribine

  • Experimental
    Sarilumab 200 mg q2w + DMARDs

    Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.

    Drug: Sarilumab · Drug: Sulfasalazine · Drug: Leflunomide · Drug: Bucillamine · Drug: Tacrolimus · Drug: Mizoribine

  • Experimental
    Sarilumab 150 mg q2w

    Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.

    Drug: Sarilumab

  • Experimental
    Sarilumab 200 mg q2w

    Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.

    Drug: Sarilumab

Interventions

  • Pharmaceutical form:solution

    Also known as: SAR153191 (REGN88)

  • Pharmaceutical form: Tablet Route of administration: Oral

  • Pharmaceutical form: Tablet Route of administration: Oral

  • Pharmaceutical form: Tablet Route of administration: Oral

  • Pharmaceutical form: Capsule Route of administration: Oral

  • Pharmaceutical form: Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Adverse event (AE) was defined as any untoward medical occurrence in a participant who received IMP and did not necessary have to had a causal relationship with treatment. All AEs that occurred from the first dose of the IMP administration up to 6 weeks after last dose of treatment (up to Week 58) were considered as TEAEs. SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. TEAEs included both SAEs and non-SAEs.

    Time frame: Baseline up to Week 58

  2. Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities

    Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP) supine: \<=95 mmHg and decrease from baseline (DFB) \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB ≥10 mmHg * SBP (Orthostatic): \<=-20 mmHg * DBP (Orthostatic): \<=-10 mmHg * Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB

    Time frame: Baseline up to Week 58

  3. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

    Criteria for potentially clinically significant ECG abnormalities: * PR Interval: \>200 milliseconds (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QT Interval: \>500 ms * QTc Bazett (QTc B): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms, IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms

    Time frame: Baseline up to Week 58

  4. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters

    Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female\[F\]); \>=185 g/L (M) or \>=165 g/L (F); DFB \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<50 Giga/L; \>=50 and \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \<0.5 Giga/L; \>=0.5 Giga/L and \<lower limit of normal (LLN); \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)

    Time frame: Baseline up to Week 58

  5. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters

    Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Hemoglobin A1c (HbA1c): \>8% * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L

    Time frame: Baseline up to Week 58

  6. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes

    Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L

    Time frame: Baseline up to Week 58

  7. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters

    Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min * Blood urea nitrogen: \>=17 mmol/L * Uric acid: \<120 micromol/L; \>408 micromol/L

    Time frame: Baseline up to Week 58

  8. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

    Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN * Conjugated bilirubin(CBILI): \>1.5 ULN * Unconjugated bilirubin: \>1.5 ULN * ALT \>3 ULN and TBILI \>2 ULN * CBILI \>35% TBILI and TBILI \>1.5 ULN * Albumin: \<=25 g/L

    Time frame: Baseline up to Week 58

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology (ACR) 20, 50 and 70 Responses at Week 52

    ACR response is a composite rating scale that includes 7 variables: tender joints count (TJC \[68 joints\]); swollen joints count (SJC \[66 joints\]); levels of an acute phase reactant (high sensitivity C-reactive protein \[hs-CRP level\]); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by Health Assessment Question-Disability Index \[HAQ-DI\], with scoring range of 0 \[better health\] - 3 \[worst health\]). ACR20/50/70 response is defined as at least 20/50/70% improvement in both TJC and SJC, and at least 20/50/70% improvement in at least 3 of the 5 other assessments, respectively.

    Time frame: Week 52

  2. Change From Baseline at Week 52 in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP)

    DAS28-CRP is a composite score that contains 4 variables: TJC (based on 28 joints), SJC (based on 28 joints), participant's assessment of general health on VAS (range 0 \[very well\] to 100 mm \[extremely bad\]) and CRP (mg/L). DAS28-CRP total score ranges from 2-10 with a lower score indicating less disease activity. A DAS28-CRP above 5.1 indicates high disease activity, whereas below 3.2 indicates low disease activity and below 2.6 as disease remission.

    Time frame: Baseline, Week 52

  3. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52

    HAQ-DI assessed the degree of difficulty participants experienced in 8 daily living activity domains during a week: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consisted of 2-3 items. Each items's difficulty was scored from 0-3 (0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do). Overall HAQ-DI score was computed as the sum of domain scores divided by the number of domains answered, providing a score from 0-3. Low scores denoted improvement of disability/lower degree of domain difficulty.

    Time frame: Baseline, Week 52

07

Results

Posted Jan 30, 2018

Participant flow

This study was conducted at 40 centers in Japan. A total of 117 participants were screened between 23 February 2015 and 9 September 2015, 26 of whom were screen failures.

Participant flow — Overall Study
MilestoneSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
Started15153031
Completed1392730
Not completed2631
Withdrew: Adverse event2521
Withdrew: Lack of efficacy0010
Withdrew: Other0100

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Adverse event (AE) was defined as any untoward medical occurrence in a participant who received IMP and did not necessary have to had a causal relationship with treatment. All AEs that occurred from the first dose of the IMP administration up to 6 weeks after last dose of treatment (up to Week 58) were considered as TEAEs. SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. TEAEs included both SAEs and non-SAEs.

Time frame:
Baseline up to Week 58
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
Any TEAE14132528
SAE0312
PrimaryNumber of Participants With Potentially Clinically Significant Vital Signs Abnormalities

Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP) supine: \<=95 mmHg and decrease from baseline (DFB) \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg * Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB ≥10 mmHg * SBP (Orthostatic): \<=-20 mmHg * DBP (Orthostatic): \<=-10 mmHg * Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm * Weight: \>=5% DFB; \>=5% IFB

Time frame:
Baseline up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
participantsSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
SBP (supine) <=95 mmHg and DFB >=20 mmHg0000
SBP (supine) >=160 mmHg and IFB >=20 mmHg1111
DBP (supine) <=45 mmHg and DFB >=10 mmHg0000
DBP (supine) >=110 mmHg and IFB >=10 mmHg0000
SBP (orthostatic) <=-20 mmHg8559
DBP (orthostatic) <=-10 mmHg33510
HR (supine) <=50 bpm and DFB >= 20 bpm0011
HR (supine) >=120 bpm and IFB >=20 bpm0000
Weight >=5% DFB1120
Weight >=5% IFB32127
PrimaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

Criteria for potentially clinically significant ECG abnormalities: * PR Interval: \>200 milliseconds (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25% * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25% * QT Interval: \>500 ms * QTc Bazett (QTc B): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms, IFB \>60 ms * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms

Time frame:
Baseline up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
participantsSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
PR >200 ms0001
PR >200 ms and IFB >=25%0000
PR >220 ms0001
PR >220 ms and IFB >=25%0000
PR >240 ms0000
PR >240 ms and IFB >=25%0000
QRS >110 ms0201
QRS >110 ms and IFB >=25%0000
QRS >120 ms0200
QRS >120 ms and IFB >=25%0000
QT >500 ms0001
QTc B >450 ms21610
QTc B >480 ms0101
QTc B >500 ms0000
QTc B IFB >30 and <=60 ms0121
QTc B IFB >60 ms0000
QTc F >450 ms2126
QTc F >480 ms0001
QTc F >500 ms0000
QTc F IFB >30 and <=60 ms0000
QTc F IFB >60 ms0000
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters

Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female\[F\]); \>=185 g/L (M) or \>=165 g/L (F); DFB \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<50 Giga/L; \>=50 and \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \<0.5 Giga/L; \>=0.5 Giga/L and \<lower limit of normal (LLN); \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)

Time frame:
Baseline up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters
participantsSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
Hemoglobin <=115 g/L (M) or <=95 g/L (F)0113
Hemoglobin >=185 g/L (M) or >=165 g/L (F)0000
Hemoglobin DFB >=20 g/L0002
Hematocrit <=0.37 v/v (M) or <=0.32 v/v (F)0326
Hematocrit >0.55 v/v (M) or >=0.5 v/v (F)0000
RBC >=6 Tera/L0000
Platelets <50 Giga/L0000
Platelets >=50 and <100 Giga/L1110
Platelets >=700 Giga/L0000
WBC <3.0 Giga/L (NB) or <2.0 Giga/L (B)6979
WBC >=16.0 Giga/L0000
Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B)811813
Neutrophils <1.0 Giga/L5324
Lymphocytes <0.5 Giga/L0001
Lymphocytes >=0.5 Giga/L and <LLN3438
Lymphocytes >4.0 Giga/L0100
Monocytes >0.7 Giga/L1032
Basophils >0.1 Giga/L1005
Eosinophils >0.5 Giga/L or >ULN (ULN >=0.5 Giga/L)0022
SecondaryPercentage of Participants Achieving American College of Rheumatology (ACR) 20, 50 and 70 Responses at Week 52

ACR response is a composite rating scale that includes 7 variables: tender joints count (TJC \[68 joints\]); swollen joints count (SJC \[66 joints\]); levels of an acute phase reactant (high sensitivity C-reactive protein \[hs-CRP level\]); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by Health Assessment Question-Disability Index \[HAQ-DI\], with scoring range of 0 \[better health\] - 3 \[worst health\]). ACR20/50/70 response is defined as at least 20/50/70% improvement in both TJC and SJC, and at least 20/50/70% improvement in at least 3 of the 5 other assessments, respectively.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology (ACR) 20, 50 and 70 Responses at Week 52
percentage of participantsSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
ACR2073.340.076.774.2
ACR5060.033.356.754.8
ACR7053.326.726.725.8
SecondaryChange From Baseline at Week 52 in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP)

DAS28-CRP is a composite score that contains 4 variables: TJC (based on 28 joints), SJC (based on 28 joints), participant's assessment of general health on VAS (range 0 \[very well\] to 100 mm \[extremely bad\]) and CRP (mg/L). DAS28-CRP total score ranges from 2-10 with a lower score indicating less disease activity. A DAS28-CRP above 5.1 indicates high disease activity, whereas below 3.2 indicates low disease activity and below 2.6 as disease remission.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Baseline at Week 52 in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP)
units on a scaleSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline at Week 52 in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP)-2.90 ± 1.06-2.47 ± 0.84-2.62 ± 1.12-2.64 ± 1.35
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52

HAQ-DI assessed the degree of difficulty participants experienced in 8 daily living activity domains during a week: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consisted of 2-3 items. Each items's difficulty was scored from 0-3 (0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do). Overall HAQ-DI score was computed as the sum of domain scores divided by the number of domains answered, providing a score from 0-3. Low scores denoted improvement of disability/lower degree of domain difficulty.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
units on a scaleSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52-0.52 ± 0.45-0.34 ± 0.60-0.48 ± 0.58-0.38 ± 0.34
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters

Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Hemoglobin A1c (HbA1c): \>8% * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L

Time frame:
Baseline up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters
participantsSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
Glucose <=3.9 mmol/L and <LLN0011
Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas)0102
HbA1c >8%0001
Total Cholesterol >=6.2 mmol/L671213
Total Cholesterol >=7.74 mmol/L1112
LDL Cholesterol >=4.1 mmol/L1363
LDL Cholesterol >=4.9 mmol/L0121
Triglycerides >=4.6 mmol/L0001
Triglycerides >=5.6 mmol/L0001
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes

Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L * Potassium: \<3 mmol/L; \>=5.5 mmol/L * Chloride: \<80 mmol/L; \>115 mmol/L

Time frame:
Baseline up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes
participantsSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
Sodium <=129 mmol/L0000
Sodium >=160 mmol/L0000
Potassium <3 mmol/L0000
Potassium >=5.5 mmol/L0000
Chloride <80 mmol/L0000
Chloride >115 mmol/L0000
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters

Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min * Blood urea nitrogen: \>=17 mmol/L * Uric acid: \<120 micromol/L; \>408 micromol/L

Time frame:
Baseline up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters
participantsSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
Creatinine >=150 micromol/L (Adults)0001
Creatinine >=30% change from baseline3365
Creatinine >=100% change from baseline0000
Creatinine Clearance <15 mL/min0000
Creatinine clearance >=15 to <30 mL/min0000
Creatinine clearance >=30 to <60 mL/min6665
Creatinine clearance >=60 to <90 mL/min871517
Blood Urea Nitrogen >=17 mmol/L0000
Uric acid <120 micromol/L0100
Uric acid >408 micromol/L1124
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters

Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN * Alkaline phosphatase: \>1.5 ULN * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN * Conjugated bilirubin(CBILI): \>1.5 ULN * Unconjugated bilirubin: \>1.5 ULN * ALT \>3 ULN and TBILI \>2 ULN * CBILI \>35% TBILI and TBILI \>1.5 ULN * Albumin: \<=25 g/L

Time frame:
Baseline up to Week 58
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
participantsSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2w
ALT >1 ULN and <=1.5 ULN3476
ALT >1.5 ULN and <=3 ULN2132
ALT >3 ULN and <=5 ULN1014
ALT >5 ULN and <=10 ULN1000
ALT >10 ULN and <=20 ULN0000
ALT >20 ULN0000
AST >1 ULN and <=1.5 ULN6584
AST >1.5 ULN and <=3 ULN1023
AST >3 ULN and <=5 ULN1001
AST >5 ULN and <=10 ULN0000
AST >10 ULN and <=20 ULN0000
AST >20 ULN0000
Alkaline Phosphatase >1.5 ULN0000
TBILI >1.5 ULN1100
TBILI >2 ULN0000
CBILI >1.5 ULN0000
Unconjugated Bilirubin >1.5 ULN0000
ALT> 3 ULN and TBILI >2ULN0000
CBILI >35% TBILI and TBILI >1.5 ULN0000
Albumin <=25 g/L0000

Adverse events

Collected over All AEs were collected from signature of the informed consent form until the end of the study (Week 58) regardless of seriousness or relationship to IMP.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sarilumab 150 mg q2w + DMARDs0/15 (0%)0/15 (0%)14/15 (93.3%)
Sarilumab 200 mg q2w + DMARDs0/15 (0%)3/15 (20%)13/15 (86.7%)
Sarilumab 150 mg q2w Monotherapy0/30 (0%)1/30 (3.3%)22/30 (73.3%)
Sarilumab 200 mg q2w Monotherapy0/31 (0%)2/31 (6.5%)23/31 (74.2%)
Most frequent serious events
Most frequent serious events
EventSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2w MonotherapySarilumab 200 mg q2w Monotherapy
Chronic sinusitisInfections and infestations0/151/150/300/31
Periorbital abscessInfections and infestations0/151/150/300/31
Breast cancer femaleNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/151/150/300/31
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/151/150/300/31
Herpes zoster oticusInfections and infestations0/150/151/300/31
Pneumonia bacterialInfections and infestations0/150/150/301/31
Abortion inducedSurgical and medical procedures0/150/150/301/31
Most frequent other events
Showing 10 of 67
Most frequent other events
EventSarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2w MonotherapySarilumab 200 mg q2w Monotherapy
NasopharyngitisInfections and infestations4/155/1513/3014/31
NeutropeniaBlood and lymphatic system disorders5/153/151/303/31
StomatitisGastrointestinal disorders3/154/153/304/31
ContusionInjury, poisoning and procedural complications3/150/152/300/31
Injection site erythemaGeneral disorders0/151/151/306/31
GastroenteritisInfections and infestations2/150/151/301/31
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/150/154/302/31
DizzinessNervous system disorders0/152/152/301/31
Hepatic function abnormalHepatobiliary disorders1/150/151/304/31
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/150/153/302/31

Baseline characteristics

Modified intent-to-treat (mITT) population included all randomized participants who received at least one dose of investigational medicinal product (IMP), irrespective of compliance with the study protocol and procedures.

Age, Continuous
Age, Continuous(years)Sarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2wTotal
Mean56.3 ± 10.963.3 ± 10.654.4 ± 13.852.5 ± 10.355.6 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Sarilumab 150 mg q2w + DMARDsSarilumab 200 mg q2w + DMARDsSarilumab 150 mg q2wSarilumab 200 mg q2wTotal
Female1213272678
Male323513
08

Study locations

40 sites
  • Investigational Site Number 392010
    Asahi-Shi, Japan
  • Investigational Site Number 392001
    Asahikawa-Shi, Japan
  • Investigational Site Number 392070
    Beppu-Shi, Japan
  • Investigational Site Number 392036
    Chiba-Shi, Japan
  • Investigational Site Number 392083
    Chuo-Ku, Japan
  • Investigational Site Number 392004
    Fukui-Shi, Japan
  • Investigational Site Number 392039
    Fukuoka-Shi, Japan
  • Investigational Site Number 392030
    Ichinomiya-Shi, Japan
  • Investigational Site Number 392002
    Iizuka-Shi, Japan
  • Investigational Site Number 392019
    Kagoshima-Shi, Japan
  • Investigational Site Number 392066
    Kamakura-Shi, Japan
  • Investigational Site Number 392050
    Kato-Shi, Japan
  • Investigational Site Number 392037
    Kawachi-Nagano-Shi, Japan
  • Investigational Site Number 392099
    Kawasaki-Shi, Japan
  • Investigational Site Number 392013
    Kitakyushu-Shi, Japan
  • Investigational Site Number 392097
    Kochi-Shi, Japan
  • Investigational Site Number 392065
    Kushiro-Shi, Japan
  • Investigational Site Number 392026
    Matsuyama-Shi, Japan
  • Investigational Site Number 392034
    Miyagi-Gun, Japan
  • Investigational Site Number 392076
    Nagoya-Shi, Japan
  • Investigational Site Number 392080
    Nagoya-Shi, Japan
  • Investigational Site Number 392046
    Narashino-Shi, Japan
  • Investigational Site Number 392059
    Oita-Shi, Japan
  • Investigational Site Number 392062
    Okayama-Shi, Japan
  • Investigational Site Number 392027
    Osaki-Shi, Japan
  • Investigational Site Number 392049
    Sagamihara-Shi, Japan
  • Investigational Site Number 392014
    Sapporo-Shi, Japan
  • Investigational Site Number 392041
    Sapporo-Shi, Japan
  • Investigational Site Number 392073
    Sapporo-Shi, Japan
  • Investigational Site Number 392006
    Sasebo-Shi, Japan
  • Investigational Site Number 392021
    Sendai-Shi, Japan
  • Investigational Site Number 392022
    Sendai-Shi, Japan
  • Investigational Site Number 392033
    Sendai-Shi, Japan
  • Investigational Site Number 392071
    Sendai-Shi, Japan
  • Investigational Site Number 392029
    Shizuoka-Shi, Japan
  • Investigational Site Number 392023
    Takaoka-Shi, Japan
  • Investigational Site Number 392003
    Tomakomai-Shi, Japan
  • Investigational Site Number 392074
    Urasoe-Shi, Japan
  • Investigational Site Number 392079
    Urayasu-Shi, Japan
  • Investigational Site Number 392048
    Yokohama-Shi, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2015
First posted
Feb 26, 2015
Start
Feb 2015
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Results first posted
Jan 30, 2018
Last update
Jan 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02373202
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 26, 2015
Start date
Feb 2015
Primary completion
Nov 2016
Completion
Nov 2016
Results posted
Jan 30, 2018
Last update
Jan 30, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion